Manisha Samy

Stanford-trained scientist | Ex-ARK Invest @arkinvest, MSKCC, Biotech strategist | Drug dev, VC, AI x Bio. Faith-led. Prayer warrior. Purpose over hype.

[Manisha Samy @MSamy_7]

I’m Manisha — Stanford alum, biotech strategist, and woman of faith.

I break down venture capital & drug development.
I also lead bold prayers & Spirit-led intercession by night.

Follow for biotech insights + purpose-driven leadership.

Faith. Science. Calling.
@MSamy_7

[Simon Erickson @7Innovator]

It costs $2.5 billion and up to 10 years of effort to successfully bring a new drug to market.

That's an extremely high hurdle to succeed!

It's no wonder why the high costs of FDA trials & the elevated rates of failure often result in small-cap drug developers declaring bankruptcy. Biotechnology is one of the stock market's riskiest sectors to invest in.

But what if there was a way to change that?

What if we could use technology to alleviate some of the biotech industry's deepest and most systemic risks?

AI doesn't necessarily produce better drugs. Though it might be able to reduce drug development costs and timelines significantly.

And if it did, that would be a game-changer for the entire industry.

On today's 7investing livestream, my special guest Manisha Samy @MSamy_7 and I will discuss how AI-native infrastructure could vastly improve the return profiles of early-stage biotech companies.

Our stock of focus will be Recursion Pharmaceuticals $RXRX, who's creatively using AI to guide several programs in its development pipeline.

Manisha and I are excited to chat about biotech with you on this pre-Valentine's Day Friday the 13th.

Grab a coffee and jot down some questions. We'll open up the livestream event at 10 AM ET!

https://t.co/w8EsNyHVR0

[Simon Erickson @7Innovator]

Happy New Year and I hope you had a wonderful holiday!

In today's 7investing Live, I explain why I'm excited to get back in the saddle and what's coming up for our livestream show in 2026.

As individual investors, we have several unique advantages over institutions that allow us to avoid style-box limitations and to venture beyond herd mentality.

We've also been doing things completely wrong in the investing newsletter industry.

Rather than independently operating siloed newsletters, we should find opportunities to collaborate with others and to expand our peripheral vision.

In January's upcoming shows, I'll be featuring several guests including Spencer Randall from CryptoEQ, Emmet Savage from MyWallSt, James Early from Curia Financial, and former 7i advisors Manisha Samy and Steve Symington.

There's a lot for investors to look forward to in 2026! See you every MWF at 10 AM ET this year!

@CryptoEQ @emmetlsavage @JamesEarly_ @MSamy_7 @Steve_Symington

https://t.co/UqnSIjfoPo

[Manisha Samy @MSamy_7]

It’s appalling to me that there is not more uproar about this absolutely bone-chilling terror attack in broad daylight. Is it because we cannot directly spin it into a Right vs Left political debate?

[Manisha Samy @MSamy_7]

Sarepta up on the news today. Some of us saw this coming 👀
Always bet on science and UTILITY. $SRPT

[Manisha Samy @MSamy_7]

1/
Sarepta $SRPT has refused the FDA’s request to halt Elevidys shipments to ambulatory Duchenne patients.

This has triggered backlash—but here’s a breakdown of the complex truth behind that decision. 🧵👇

[Prof. Nikolai Slavov @slavov_n]

How challenging is the prediction of transcriptional responses to CRISPR gene perturbations ?

A simple model, just scaling RNA correlation vectors, results in accurate predictions for many perturbations.

The model is intuitive & grounded in a simple approximation.

1/2

[Manisha Samy @MSamy_7]

@jacobg0121 How would you respond to parents with no other therapeutic alternatives? What’s the best case scenario for ambulatory patients? To pull the drug? I’m curious to know what a proper response would be.

[Manisha Samy @MSamy_7]

1/
Sarepta $SRPT has refused the FDA’s request to halt Elevidys shipments to ambulatory Duchenne patients.

This has triggered backlash—but here’s a breakdown of the complex truth behind that decision. 🧵👇

[Manisha Samy @MSamy_7]

10/
Sarepta’s decision to keep Elevidys available for ambulatory boys isn’t without controversy.

But for many, it’s a lifeline.
And for Duchenne, where time is muscle—time matters.

#Duchenne #Elevidys #RareDisease #GeneTherapy

[Manisha Samy @MSamy_7]

9/
This moment demands rigor and empathy.
It’s possible to grieve the lives lost AND fight to protect the ones still fighting.

Let’s not pit parents against each other.
Let’s listen. Learn. And act with wisdom and compassion.

[Manisha Samy @MSamy_7]

Investors: stop pinning hopes on data bursts. Bet on platform biotech—durable, scalable, multi-asset upside.
#Biotech #PlatformFirst #LongTerm $SEPN $CRSP $RXRX $NTLA

[Manisha Samy @MSamy_7]

Too many investors are chasing short-term data. The smart play? ✅ Platform + proof = long-term alpha. One engine, multiple shots, sustainable upside. Here’s the resume of winners: 🧬👇

[Manisha Samy @MSamy_7]

🎯 Key edge: proof-backed platforms > hype. These names have real clinical & deal signals—with room to run.